On October 1, 2021 ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company"), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, reported that four abstracts have been accepted for presentation at the SITC (Free SITC Whitepaper) 36th Annual Meeting in Washington D.C. from November 10 –14, 2021 (Press release, ALX Oncology, OCT 1, 2021, View Source [SID1234591866]). The abstracts, which will be presented in a poster session, include new clinical data from ASPEN-01, the ongoing Phase 1b study of evorpacept (also known as ALX148) in patients with head and neck squamous cell carcinoma and with gastric/gastroesophageal cancer, and clinical trial in progress presentations on ASPEN-03 and ASPEN-04, our Phase 2 head and neck cancer studies in collaboration with Merck. In addition, preclinical data will be presented on ALTA-002, a first-in-class SIRPα-directed TLR9 agonist antibody conjugate, which is being developed in collaboration with Tallac Therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Title: Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 (Abstract 498)

Presentation Time: November 12 – 14, 2021, 7:00am – 5:00pm ET

Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 (Abstract 439)

Presentation Time: November 12 – 14, 2021, 7:00am – 5:00pm ET

Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 (Abstract 433)

Presentation Time: November 12 – 14, 2021, 7:00am – 5:00pm ET

Location: Poster Hall

Title: ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (Abstract 780)

Presentation Time: November 12 – 14, 2021, 7:00am – 5:00pm ET

Location: Poster Hall

On October 1, 2021 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported it will present four posters at SITC (Free SITC Whitepaper)’s 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021 (Press release, Shattuck Labs, OCT 1, 2021, View Source [SID1234591769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Abstract Title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer
Abstract Number: 429
Presenter: Nehal J. Lakhani, MD, PhD, START Midwest
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint (ARC) Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas
Abstract Number: 494
Presenter: Melissa Johnson, MD, Sarah Cannon Research Institute
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics That Stimulate Target Cells to Migrate from the Peripheral Blood
Abstract Number: 3
Presenter: Louis Gonzalez, PhD, Shattuck’s Director of Translational Research
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-tumor Immunity in the Setting of PD-1 and TIGIT Checkpoint Blockade
Abstract Number: 585
Presenter: George Fromm, PhD, Shattuck’s Vice President of Research & Development
Date: November 12th – 14th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Further information about the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting can be found at:
View Source

On October 1, 2021 T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting taking place November 10-14, 2021 (Press release, T-Knife, OCT 1, 2021, View Source [SID1234591706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"TK-8001 is a novel CD8 TCR-T targeting MAGE-A1, a tumor-specific antigen associated with aggressive cancers and poor clinical prognosis," stated Eugen Leo, Chief Medical Officer of T-knife. "The presentations at SITC (Free SITC Whitepaper) will cover important aspects of our work related with TK-8001, including favorable preclinical data comparing TK-8001 to human donor-derived TCRs, the potential benefits of MAGE-A1 as a cancer target, and the design of our forthcoming IMAG1NE Phase 1/2 study intended to evaluate the safety and efficacy of TK-8001 in select patients with MAGE-A1 expressing solid tumors."

Poster Presentation Details

Title: Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs
Abstract ID: 225
Date: Friday, Nov. 12, 2021
Time: 7:00 am – 5:00 pm

Title: MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy
Abstract ID: 95
Date: Friday, Nov. 12, 2021
Time: 7:00 am – 5:00 pm

Title: A first-in-human, Phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The "IMAG1NE" trial)
Abstract ID: 499
Date: Friday, Nov. 12, 2021
Time: 7:00 am – 5:00 pm

About TK-8001 TCR-T
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no reported protein expression in healthy tissues other than testis and significant consistency of expression between the primary tumor and metastases. As high affinity TCRs specific for MAGE-A1 peptides in humans are eliminated through central tolerance, we believe our HuTCR platform is a differentiated means to discover and select MAGE-A1 specific TCRs with an optimal affinity and high specificity profile.

About the IMAG1NE Phase 1/2 Trial
The IMAG1NE Phase 1/2 trial is an open-label, multi-center Phase 1/2 trial designed to evaluate the safety and efficacy of TK-8001 in patients with MAGE-A1 positive solid tumors. The Phase 1 portion of the IMAG1NE trial is planned to enroll approximately 6 to 18 patients to assess the initial safety and tolerability of ascending dose levels of TK-8001. A key outcome of the Phase 1 portion of the trial is to select a dose to be evaluated in the Phase 2 part of the study. The Phase 2 portion of the IMAG1NE trial is designed to enroll approximately 30 additional participants to assess the efficacy of TK-8001 across a range of tumor indications.

On October 1, 2021 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported three upcoming poster presentations at the 36th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) Annual Meeting, to be held in Washington, D.C., as well as virtually November 10-14, 2021 (Press release, Apexigen, OCT 1, 2021, View Source [SID1234590984]). Sotigalimab, Apexigen’s lead immuno-oncology therapeutic, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Title of the Presentation: Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Abstract ID: 389
Presenter: Harriet Kluger, M.D., Professor of Medical Oncology at Yale School of Medicine

Title of the Presentation: Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
Abstract ID: 343
Presenter: Deena Maurer, Ph.D., Translational and Regulatory Affairs Scientist Fellow at the Parker Institute for Cancer Immunotherapy

Title of the Presentation: INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses
Abstract ID: 411
Presenter: Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center

The posters will be available on-demand through the SITC (Free SITC Whitepaper) conference portal starting Friday, November 12, 2021, at 7:00 a.m. ET.

On October 1, 2021 BioNTech SE (BNTX) reported the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a phase 2 trial (Press release, BioNTech, OCT 1, 2021, View Source [SID1234590695]). It is planned to enroll about 200 patients to evaluate the efficacy of BNT122 compared to watchful waiting after surgery and chemotherapy. The trial has been initiated in the United States, Germany, Spain and Belgium.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Özlem Türeci, Chief Medical Officer of BioNTech, said: "Many cancers progress in such a way that the patient initially appears tumor-free after surgery, but after some time tumor foci that were initially invisible grow and form metastases. In this clinical trial in patients with colorectal cancer, we aim to identify high-risk patients with a blood test and investigate whether an individualized mRNA vaccine can prevent such relapses."